At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 504 enrolled
Drug / intervention
Nivolumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Randomized Multinational Phase 3 Trial of Nivolumab Versus Docetaxel in Previously Treated Subjects With Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 078: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 078)
In Brief
A Phase 3 clinical trial evaluating Nivolumab and Docetaxel for Non-Small Cell Lung Cancer. Completed, enrolled 504 participants across 33 sites in 4 countries.
Detailed Summary
The purpose of this study is to determine whether Nivolumab improves life expectancy compared to Docetaxel in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who have failed prior platinum-based doublet chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesChina, Hong Kong, Russia, Singapore
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartDec 2015
Primary CompletionSep 2017
Study CompletionNov 2023
TodayJul 2026
First PostedNov 24, 2015
Enrollment StartDec 11, 2015
Primary CompletionSep 15, 2017
Study CompletionNov 24, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 10.6 years ago
Interventions
Nivolumabdrug
Docetaxeldrug